April 2017 in “Journal of Investigative Dermatology” Sirolimus and propranolol may reduce abnormal cell growth and improve lymphatic malformations in children.
9 citations
,
October 2025 in “MedComm” PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
12 citations
,
September 2002 in “Epilepsia” Monitoring new epilepsy drugs after they're sold is crucial to find rare and long-term side effects that initial tests might miss.
November 2025 in “Journal of Investigative Dermatology” IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.
June 2005 in “Journal of Investigative Dermatology” The journal emphasizes the importance of combining basic and clinical science to improve health.
May 2024 in “Journal of the Egyptian Womenʼs Dermatologic Society” Diphenylcyclopropenone is effective and safe for treating severe alopecia areata in children, with maintenance therapy reducing relapse risk.
January 2026 in “JPRAS Open” PDLLA scalp injections improved hair regrowth in most patients with non-scarring alopecia.
4 citations
,
January 1987 in “Journal of The American Academy of Dermatology” A man with both skin lesions and lung cancer improved quickly with chemotherapy, suggesting the skin condition might be a reaction to immune system injury.
2 citations
,
May 2011 in “Journal of Clinical Oncology” Further testing of paclitaxel poliglumex for this cancer treatment is not justified.
1 citations
,
September 2007 in “Neuromuscular disorders” The treatment with valproate, acetylcarnitine, folic acid, and vitamin B12 may improve muscle strength in children with SMA without significant side effects.
July 2024 in “Journal of Investigative Dermatology”
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Machine learning can predict how well patients with alopecia areata will respond to certain treatments.
1461 citations
,
March 2004 in “Annals of oncology” Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.
Lupus is a complex disease that requires personalized treatment because it varies greatly between individuals.
12 citations
,
March 2021 in “Patient Preference and Adherence” Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.
June 2010 in “Melanoma research” LDE225 is a promising skin-applied treatment for basal cell carcinoma with good skin penetration and effectiveness.
March 2006 in “Drug Discovery Today: Therapeutic Strategies” The 2006 editorial concluded that immunotherapy was advancing with new drugs, focusing on specific biological therapies and convenient oral treatments, and highlighted the importance of partnerships and new regulations in the field.
15 citations
,
November 2022 in “Cell Death and Disease” CEP135 may predict cancer outcomes, and targeting PLK1 could help treat certain sarcomas.
July 2024 in “Journal of Investigative Dermatology” ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.
December 2025 in “Pharmaceutics” EV-based drug delivery shows promise but faces challenges in standardization and scalability.
September 2023 in “Journal of the American Academy of Dermatology” Oral difelikefalin significantly reduces itch in notalgia paresthetica.
February 2026 in “Journal of Dermatological Treatment” CG2001 is safe and well-tolerated for treating hair loss, with fewer side effects than oral finasteride.
1 citations
,
November 2022 in “Journal of the Endocrine Society” Adults with classic congenital adrenal hyperplasia value medication that prevents weight gain from glucocorticoids the most.
1 citations
,
November 2025 in “International Journal of Dermatology” The AAcQLI is a promising tool for assessing quality of life in children with alopecia areata.
September 2023 in “Journal of the American Academy of Dermatology”
January 2024 in “Wiadomości Lekarskie” AI and new therapies show promise in medicine, especially for cancer and regenerative treatments.
RCS-01 cell therapy is safe and improves skin gene expression.
January 2026 in “The FASEB Journal” The trial aims to test a new treatment for hair loss in young men using stem cell-derived vesicles.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
4 citations
,
May 2018 in “Journal of Neuro-Ophthalmology” New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.